# Saccharomyces cerevisiae CNCM I-1077

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/saccharomyces-cerevisiae-cncm-i-1077
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-31
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** LEVUCELL® SC, S. cerevisiae CNCM I-1077, Saccharomyces cerevisiae strain I-1077, CNCM I-1077

## Overview

Saccharomyces cerevisiae CNCM I-1077 is a specific probiotic yeast strain currently studied only in veterinary applications for [digestive health](/ingredients/condition/gut-health) support. This strain contains [beta-glucan](/ingredients/condition/immune-support)s and mannanoligosaccharides that may improve microbial colonization in animal digestive systems.

## Health Benefits

• Currently no documented human health benefits - this strain is only studied in veterinary applications • May support [digestive health](/ingredients/condition/gut-health) in animals through improved rumen microbial colonization (animal studies only) • Related S. cerevisiae strains show [anti-inflammatory](/ingredients/condition/inflammation) effects in animal colitis models (different strain, not CNCM I-1077) • No human clinical trials or systematic reviews available for this specific strain • Evidence limited to veterinary feed applications without human health data

## Mechanism of Action

CNCM I-1077 contains [beta-glucan](/ingredients/condition/immune-support)s in its cell wall that may stimulate immune responses through Toll-like receptor activation. The strain's mannanoligosaccharides potentially act as [prebiotic](/ingredients/condition/gut-health)s, promoting beneficial bacterial growth in the digestive tract. Related S. cerevisiae strains modulate [inflammatory pathway](/ingredients/condition/inflammation)s by reducing NF-kappaB activation and cytokine production.

## Clinical Summary

Currently, no human clinical studies exist for Saccharomyces cerevisiae CNCM I-1077, with research limited exclusively to veterinary applications. Animal studies in ruminants suggest improved digestive microbial balance, but specific study details including sample sizes and quantified outcomes are not well-documented in peer-reviewed literature. Related S. cerevisiae strains have shown [anti-inflammatory](/ingredients/condition/inflammation) effects in animal colitis models, but this specific strain lacks human safety and efficacy data. The evidence base remains insufficient for human supplementation recommendations.

## Nutritional Profile

Saccharomyces cerevisiae CNCM I-1077 is a single-celled fungal organism; as a probiotic/fermentation ingredient, it contributes minimal macronutrient load at typical dosing levels (product-dependent, often 1–10 billion CFU/dose). General S. cerevisiae compositional data (per 100g dry cell mass, extrapolated from well-characterized strains): Protein: 40–50g (rich in glutamic acid, aspartic acid, leucine; contains all essential amino acids); Carbohydrates: 35–45g (primarily cell wall beta-1,3/1,6-glucans ~25–30g and mannan/mannoproteins ~15–20g); Lipids: 2–5g (predominantly unsaturated fatty acids, oleic and linoleic acid). Micronutrients (per 100g dry weight, strain-specific data unavailable, based on S. cerevisiae class): B-vitamins notably thiamine (B1): ~10–15mg, riboflavin (B2): ~4–6mg, niacin (B3): ~35–50mg, pantothenic acid (B5): ~10–15mg, pyridoxine (B6): ~3–5mg, folate: ~2–3mg; Minerals: zinc ~7–10mg, selenium variable (substrate-dependent, typically 0.1–0.3mg), phosphorus ~1.5–2g (predominantly as phytic acid, reducing bioavailability), potassium ~1.5–2g, magnesium ~200–300mg. Bioactive compounds: beta-glucans ([immunomodulatory](/ingredients/condition/immune-support), cell wall-derived); mannooligosaccharides (MOS, [prebiotic](/ingredients/condition/gut-health) potential in gut/rumen); ergosterol (provitamin D2 precursor, ~5–10mg/100g dry weight, bioavailability enhanced by UV exposure). Bioavailability notes: At probiotic dose levels (mg range), macronutrient and micronutrient contributions to human dietary intake are negligible (<1% RDI). Beta-glucans and MOS are the primary functionally relevant compounds at physiological concentrations. Phytate content limits mineral bioavailability from whole-cell preparations. CNCM I-1077 strain-specific compositional data is not publicly documented in peer-reviewed literature; figures above represent S. cerevisiae species-level estimates.

## Dosage & Preparation

No clinically studied human dosages are available. In veterinary applications, LEVUCELL® SC20 provides ≥20 × 10⁹ CFU/g viable cells (uncoated powder) and LEVUCELL® SC10ME provides ≥10 × 10⁹ CFU/g (coated powder). Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Safety data for human consumption of CNCM I-1077 is unavailable since studies focus only on veterinary use. General S. cerevisiae supplementation may cause bloating, gas, or digestive discomfort in sensitive individuals. Individuals with compromised [immune system](/ingredients/condition/immune-support)s or central venous catheters should avoid yeast-based [probiotic](/ingredients/condition/gut-health)s due to potential systemic infection risk. No specific drug interactions or pregnancy safety data exists for this particular strain.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses are available for Saccharomyces cerevisiae CNCM I-1077. The strain has been studied exclusively in veterinary contexts, particularly for improving rumen microbial colonization in calves. A different S. cerevisiae strain (SC28-7) showed [anti-inflammatory](/ingredients/condition/inflammation) effects in mouse colitis models, but this research does not apply to CNCM I-1077.

## Historical & Cultural Context

No historical or traditional medicine use is documented for Saccharomyces cerevisiae CNCM I-1077, as it is a modern industrial strain selected specifically for veterinary [probiotic](/ingredients/condition/gut-health) applications. Unlike other S. cerevisiae strains such as S. boulardii which have probiotic history, this strain has no traditional use in human health.

## Synergistic Combinations

Not applicable - no human use data available

## Frequently Asked Questions

### What is Saccharomyces cerevisiae CNCM I-1077 used for?

This specific yeast strain is currently used only in veterinary applications to support digestive health in animals, particularly ruminants. No human health applications have been established for this strain.

### Is CNCM I-1077 safe for human consumption?

Safety data for human use is unavailable since research focuses exclusively on veterinary applications. General S. cerevisiae may cause digestive upset and poses infection risks for immunocompromised individuals.

### How does CNCM I-1077 differ from other S. cerevisiae strains?

CNCM I-1077 is specifically studied for veterinary digestive health applications, unlike human-studied strains like S. boulardii. This strain's unique characteristics and bioactive compound concentrations may differ from commercially available human probiotic yeasts.

### What compounds make CNCM I-1077 potentially beneficial?

The strain contains beta-glucans and mannanoligosaccharides in its cell wall structure that may support immune function and prebiotic activity. These compounds are common to S. cerevisiae but concentrations may vary by specific strain.

### Can I buy CNCM I-1077 supplements for human use?

This strain is not commercially available for human supplementation since it lacks human clinical data and safety studies. It remains restricted to veterinary applications and animal feed formulations.

### Is CNCM I-1077 approved for human use in dietary supplements?

CNCM I-1077 is not currently approved or marketed for human dietary supplements. This strain has only been studied in veterinary applications, primarily for animal digestive health. Any human use would require regulatory approval and clinical evidence, which do not yet exist for this specific strain. Consumers should verify any product claiming to contain this strain and consult regulatory databases before purchase.

### What is the difference between CNCM I-1077 and other probiotic yeasts studied in humans?

CNCM I-1077 lacks human clinical trial data, making direct comparisons to well-researched human probiotic strains difficult. Other Saccharomyces cerevisiae strains have documented human health applications, but CNCM I-1077's evidence base is limited to animal studies focusing on rumen microbial colonization. This distinction is critical—evidence from related strains cannot be assumed to apply to CNCM I-1077 in human populations. Consumers seeking proven human probiotic benefits should choose strains with established clinical research.

### Why is there limited research on CNCM I-1077 for human health?

CNCM I-1077 was specifically developed and studied for veterinary use, particularly in ruminant digestive health, which explains why human clinical trials have not been conducted. Transitioning a strain from animal-only applications to human supplements requires significant investment in regulatory studies and clinical evidence, which has not occurred for this particular strain. The lack of human data does not indicate safety concerns, but rather reflects its current narrow focus on animal agriculture applications.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*